As shown in Figure 11D–F , Nezavist alone did not alter the number of c‐Fos‐positive cells in either NTS subregion, although there was a small trend for suppression of c‐Fos‐positive cells in the anterior NTS (post hoc tests; anterior vehicle‐treated, Nezavist—placebo: p = 0.0612; posterior, vehicle‐treated, Nezavist—placebo: p = 0.45).
Treatment with Nezavist (20 mg/kg/dose) reduced the amount of alcohol ingested by drinking the 20% solution (2.16‐g/kg body weight, marginal significance, p = 0.064), and there was an increase in the quantity of alcohol consumed by drinking the 10% solution (also 2.16‐g/kg body weight for the 10% solution, p = 0.151 compared with vehicle‐treated animals) (Figure 1E ).
Although treatment with both doses of Nezavist reduced the effect of LPS on immunoreactive area and object density of CD68, these changes did not reach statistical significance. 50‐mg/kg Nezavist produced a small but statistically significant increase in CD68 object intensity ( p < 0.05) (Figure 12N ).